Stem Cells Research: A Global Strategic Business Report
San Jose, CA (Vocus/PRWEB) February 17, 2011
Stem cells research is a young and emerging field that has the potential to create a paradigm shift in present world of medicine, and drug discovery. Switching from a symptomatic treatment to the one addressing the cause of the disease, stem cells have the potential to treat several debilitating diseases that hitherto were considered untreatable. Such milestones are forcing many to believe that stem cells indeed are the future of medicine. Advancement in stem cell research can help decrease the escalating healthcare cost associated with conventional methods of treatment. The market is expected to grow further, as more and more physicians are turning towards stem cell products to treat their patients. In addition to its therapeutic applications, stem cells are also finding use in drug discovery, promising new avenues in the area of drug development.
The emerging market for stem cell therapy is creating scope for further research in the field with huge investments from across the world. In 2005, the first stem cell product was introduced, and since then various stem cell technology-based therapies were developed. However, the stem cell research arena, especially the one involved with embryonic stem cells, has been embroiled in intense ethical debate for several years. Generation of embryonic stem cells necessitates the destruction of embryo. Despite the fact that stem cells can be extracted from various sources, such as umbilical cord, much of the focus is on hESCs owing to their versatility and high potential.
Of all the stem cells types, Adult Stem Cells hold superior market potential. These cells have been used in the area of medicine for over 40 years. Adult stem cells occur in cord blood tissues as well as in adult bone marrow. Mesenchymal and Hematopoietic Stem Cells, extracted from adult bone marrow, are the leading type of adult stem cells currently in demand in the area of medicine. The high potential of adult stem cells is in part due to the ethical as well as political issues that surround use of Embryonic Stem Cells, which do not form a part of the adult stem cells. Costs involved in conducting clinical trials with adult stem cells is also comparatively lower than that of embryonic stem cells, thereby making investments in this area more lucrative. Additionally, adult stem cells have witnessed several innovations in its manufacture that have eased large-scale production of therapies using these cells with no loss to the potency, further driving the potential of these cells. Pluripotent stem cell therapy, for instance, enables infusion of stem cell therapy without the need to infuse cancer-causing viruses. Barring data from few studies, adult stem cells have been largely shown to be safe and efficacious. These cells are known to be free from risks to cancer and tissue rejection. As a result, the risk involved in research investments in adult stem cells is relatively much lower when compared to embryonic stem cells.
The US represents the largest regional market for investments in adult stem cells research, as stated by the new market research report on Stem Cells Research. Despite the ban over federal funding for research in embryonic stem cells, North America is presently dominating the stem cells market. Key factors that have kept North American market on the top of the charts include advanced stem cell research infrastructure and facilities, and federal support for the research. Europe trails behind the US market. Despite significant developments in research in many countries across the region, European market for stem cells is being partially held back by issues such as opposition to embryonic stem cell research in Germany, Poland, and Italy. However, growth in the global stem cells research would be led by Rest of World market, which is forecast to be the fastest growing regional market during the analysis period. Asia emerged as the major market in the rest of world market, with countries such as Japan, China, Singapore, Korea, and Australia emerging as the major hubs for stem cells research.
Major players profiled in the report include Advanced Cell Technology Inc., Athersys Inc., Cytori Therapeutics Inc., Genzyme Corporation, Geron Corporation, International Stem Cell Corporation, Mesoblast Ltd., Osiris Therapeutics Inc., StemCells Inc., ThermoGenesis Corp., among others.
The research report titled “Stem Cells Research: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the stem cells research markets (including adult stem cells and embryonic stem cells), current market trends, key growth drivers, overview of major types of stem cells, recent product innovations/introductions, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual estimates and forecasts of investments in the area of stem cells research for the years 2006 through 2015 by the following geographic markets - US, Europe, and Rest of World.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Stem_Cells_Research_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/
# # #